First Light Asset Management, LLC Y M Abs Therapeutics, Inc. Transaction History

First Light Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$15.51 - $29.31 $8.96 Million - $16.9 Million	-577,663 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$27.47 - $37.31 $10.2 Million - $13.9 Million	-372,529 Reduced 39.21%	577,663 $16.5 Million
Q2 2021 Aug 13, 2021	BUY	$25.45 - $37.64 $151,147 - $223,543	5,939 Added 0.63%	950,192 $32.1 Million
Q1 2021 May 17, 2021	BUY	$29.16 - $51.96 $9 Million - $16 Million	308,601 Added 48.55%	944,253 $28.6 Million
Q4 2020 Feb 16, 2021	BUY	$37.86 - $54.26 $1.04 Million - $1.49 Million	27,459 Added 4.51%	635,652 $31.5 Million
Q3 2020 Nov 13, 2020	BUY	$35.13 - $43.62 $20,094 - $24,950	572 Added 0.09%	608,193 $23.3 Million
Q2 2020 Aug 14, 2020	BUY	$23.66 - $49.53 $14.4 Million - $30.1 Million	607,621 New	607,621 $26.2 Million

23.8M

19.4K

300

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $566M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Light Asset Management, LLC with notifications on news.